MAGEA3 and head and neck squamous cell carcinoma: In an earlier phase I study, Dan et al. used a panel of peptide immunomodulatory vaccines GL-0810 (targeting HPV16 E7) and GL-0817 (targeting the melanoma-associated antigen A3, MAGE-A3) to treat HPV16- and MAGE-A3-positive R/M HNSCC patients.